Skip to content

Arvinas ARVN Lease Liability Payments - Due Year Two

Lease Liability Payments - Due Year Two at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$9.18M
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$1.49M-49.3%
Nuvation Bio logo
Nuvation BioNUVB
$1.41M+68.1%

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's lease liability payments - due year two.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's lease liability payments - due year two?
Arvinas (ARVN) reported lease liability payments - due year two of $2.5M in Q1 2026.
How has Arvinas's lease liability payments - due year two changed year-over-year?
Arvinas's lease liability payments - due year two increased by 4.2% year-over-year, from $2.4M to $2.5M.
What does lease liability payments - due year two mean?
This metric identifies the total cash payments required for operating and finance leases in the second year following the current balance sheet date. It helps investors forecast long-term fixed cost commitments and cash flow requirements. It is essential for modeling the company's future solvency and operational leverage.